<code id='6E0CEDB43A'></code><style id='6E0CEDB43A'></style>
    • <acronym id='6E0CEDB43A'></acronym>
      <center id='6E0CEDB43A'><center id='6E0CEDB43A'><tfoot id='6E0CEDB43A'></tfoot></center><abbr id='6E0CEDB43A'><dir id='6E0CEDB43A'><tfoot id='6E0CEDB43A'></tfoot><noframes id='6E0CEDB43A'>

    • <optgroup id='6E0CEDB43A'><strike id='6E0CEDB43A'><sup id='6E0CEDB43A'></sup></strike><code id='6E0CEDB43A'></code></optgroup>
        1. <b id='6E0CEDB43A'><label id='6E0CEDB43A'><select id='6E0CEDB43A'><dt id='6E0CEDB43A'><span id='6E0CEDB43A'></span></dt></select></label></b><u id='6E0CEDB43A'></u>
          <i id='6E0CEDB43A'><strike id='6E0CEDB43A'><tt id='6E0CEDB43A'><pre id='6E0CEDB43A'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:674
          Astrazeneca office building -- health policy coverage from STAT
          AstraZeneca is suing the Biden administration to stop a new Medicare drug price negotiation program. Adobe

          WASHINGTON — AstraZeneca is the sixth drugmaker to pile on a legal challenge to the Biden administration’s drug pricing reform law.

          The Medicare drug price negotiation program created in the Inflation Reduction Act is set to kick off in the next week, as officials will release the names of the first 10 medicines that will be selected for the program. Medicines are eligible for selection if they are one of the highest-spend drugs for Medicare, and they have no generic competition.

          advertisement

          AstraZeneca makes drugs that could be selected for the list, and asked a Delaware district court judge to rule that Medicare acted illegally and that the law is unconstitutional.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Biotech stock slump in 2023: awaiting the turnaround
          Biotech stock slump in 2023: awaiting the turnaround

          AdobeThiswassupposedtobetheyearofthebiotechcomeback,whenpromisingnewmedicinesandhigh-dollarbuyoutswo

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Grad students accuse University of California of wage theft

          UCSanDiegostudentsprotestedatanalumnieventinMay,wheretheyaccuseduniversityleadershipofwagetheft.Cour